2011


To access this material please log in or register

Register Authorize
2011/

Effects of aldosterone blockade in patients with heart failure: a modern approach to the problem – eplerenone (part I)

Mareev V. Yu., Skvortsov A. A.

Keywords: aldosterone, CHF

DOI: 10.18087/rhfj.2011.3.1476

Review analyzes the role of aldosterone synthesis blockade and presents the results of clinical trials on the effectiveness of aldosterone antagonists in CHF.
  1. Tait SA, Tait JF, Coghlan JP. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol Cell Endocrinol. 2004;217 (1-2):1–21.
  2. Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet. 1952;2 (6727):226–228.
  3. Weber KT, Villarreal D. Aldosterone, and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71 (Suppl A):3A-11A.
  4. Yasky J, Ledesma GA, Tutera A, Collia LF. A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. Pharmatherapeutica. 1986;4 (8):480–485.
  5. Smith AG. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin. 1980;7 (2):131–136.
  6. Müller J. Spironolactone in the management of congestive heart failure: a rewiew. Clin Ther. 1986;9 (1):63–76.
  7. Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementory DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237 (4812):268–275.
  8. Корочкин И. М., Матвеева И. В. Гормональные нарушения и лечение больных с рефрактерными формами застойной сердечной недостаточности. Кардиология. 1977;17 (8):36–43.
  9. Pierpont GL, Francis GS, Cohn JN. Effect of captopril on renal function in patients with congestive heart failure. Br Heart J. 1981;46 (5):522–527.
  10. Sharpe DN, Coxon RJ. Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Phatmacol 1982;14 (Suppl 2) 161S-167S.
  11. Nicholls MG, Espiner EA, Ikram H et al. Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. J Clin Endocrinol Metab. 1981;52 (6):1253–12536.
  12. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82 (5):1730–1736.
  13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316 (23):1429–1435.
  14. Staessen J, Lijnen P, Fagard R et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91 (3):457–465.
  15. Borghi C, Boschi S, Ambrosioni E et al. Evidence of a partial escape of renin- angiotensine-aldosterone blocade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33 (1):40–45.
  16. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail. 1999;1 (4):401–406.
  17. Мареев В. Ю., Скворцов А. А., Челмакина С. М. и др. Способны ли ингибиторы АПФ эффективно контролировать активность ренин-ангиотензин-альдостероновой системы при длительном лечении хрониче­ской сердечной недостаточности? Кардиология. 1999;39 (2):27–34.
  18. Urata H, Healy BH, Stewart R et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66 (4):883–390.
  19. Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monographs on Endocrinology. – 2nd ed. – N. Y.: Springer-Verlag, 1988. – 364p.
  20. MacFadyen RJ, Lee AF, Morton JJ et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82 (1):57–61.
  21. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29 (1):13–21.
  22. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100 (10):1056–1064.
  23. Farguharson CA, Struthers AD. Spironolactone increase nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I / angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101 (6):594–597.
  24. Скворцов А. А., Мареев В. Ю., Насонова С. Н. и др. Необходима ли тройная комбинация различных групп нейрогормональных модуляторов для лечения больных со стабильной умеренной хронической сердечной недостаточностью?. (по результатам исследования САДКО-ХСН). Тер. архив. 2006;78 (9):61–71.
  25. Скворцов А. А., Мареев В. Ю., Насонова С. Н. и др. Необходима ли тройная комбинация различных групп нейрогормональных модуляторов для лечения больных со стабильной умеренной хронической сердечной недостаточностью? Тер. архив. 2006;78 (8):14–19.
  26. Golestaneh N, Klein C, Valamanesh F et al. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun. 2001;280 (5):1300–1306.
  27. Agarwal MK, Mirshahi F, Mirshahi M, Rostene W. Immunochemical detection of mineralocorticoid receptor in rat brain. Neuroendocrinology. 1993;58 (5):575–580.
  28. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83 (6):1849–1865.
  29. Weber K, Brilla C, Janicki J. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27 (3):341–348.
  30. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26 (7):809–820.
  31. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283 (5):H1802–1810.
  32. Rocha R, Stier CT Jr, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141 (10):3871–3878.
  33. Gerling IC, Sun Y, Ahokas RA et al. Aldosteronism: an immunostimulatory state preceds proinfammatory / fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003;285 (2):H813–821.
  34. Sun Y, Zhang J, Lu L et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161 (5):1773–1781.
  35. Robert V, Heymes C, Silvestre JS et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt induced fibrosis. Hypertension. 1999;33 (4):981–986.
  36. Fullerton MJ, Funder JW. Aldosterone regulates collagen output of rat cardiac fibroblasts by up-regulation of endothelin receptors. Endocrinol Soc Proc. 1998;93:511–516.
  37. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 2000;85 (10):1199–1206.
  38. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med. 1992;120 (6):893–901.
  39. Беленков Ю. Н. Ремоделирование левого желудочка: комплексный подход. Сердечная недостаточность. 2002;3 (4):161–163.
  40. Spinale FG, Coker ML, Heung LJ et al. A matrix metalloproteinase induction / activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102 (16):1944–1949.
  41. Sakata Y, Yamamoto K, Mano T et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting inhibitor. Circulation. 2004;109 (17):2143–2149.
  42. Rude MK, Duhaney TA, Kuster GM et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46 (3):555–561.
  43. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35 (1):30–34.
  44. Hayashi M, Tsutamoto T, Wada A et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2001;38 (5):1375–1382.
  45. Zannad F, Alla F, Dousset B et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from Randomized Aldactone Evaluation Study (RALES). Circulation. 2000;102 (22):2700–2706.
  46. Redfield MM, Jacobsen SJ, Burnett JC Jr et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289 (2):194–202.
  47. Fagard R, Lijnen P, Petrov V. Opposite associations of circulating aldosterone and ANP with left ventricular diastolic function in essential hypertension. J Hum Hypertens. 1998;12 (3):195–202.
  48. Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension. 1992;19 (3):270–277.
  49. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci (Lond). 1998;95 (6):687–692.
  50. Wang M. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24 (5):571–575.
  51. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens. 2002;15 (2 Pt 1):164–169.
  52. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104 (22):2673–2678.
  53. Schmidt BM, Montealegre A, Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab. 1999;84 (10):3528–3533.
  54. Farguharson CAJ, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in man: evidence for an aldosterone induced vasculopathy. Clin Sci (Lond). 2002;103 (4):425–431.
  55. Rajagopalan S, Duquaine D, King S et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105 (18):2212–2216.
  56. Mitchell BM, Smith AD, Webb RC, Dorrance AM. Aldosterone decreases endothelium-dependent relaxation by down-regulating GTP cyclohydrolase. Hypertension. 2003;42:435 (P216). Abstract.
  57. Nagata K, Obata K, Xu J et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47 (4):656–664.
  58. Kobayashi N, Honda T, Yoshida K et al. Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis. 2006;187 (1):92–100.
  59. Szmitko PE, Wang C-H, Weisel RD et al. Biomarkers of vascular disease linking inflammation to endothelial activation, part II. Circulation. 2003;108 (17):2041–2048.
  60. Falkenstein E, Tilimann HC, Christ M et al. Multiple actions of steroid hormones in focus on rapid nongenomic effects. Pharmacol Rev. 2000;52 (4):513–556.
  61. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26 (3):313–321.
  62. Wang HG, Pathan N, Ethell IM et al. Ca2+-induced apoptpsis through calcineurin dephosphorylation of BAD. Science. 1999 Apr 9;284 (5412):339–343.
  63. Mano A, Tatsumi T, Shiraishi J et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation. 2004;110 (3):317–323.
  64. Kasama S, Toyama T, Kumakura H et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41 (4):574–581.
  65. Francis J, Weiss RM, Wei SG et al. Central mineralocorticoid receptor blockade improves volume regulation and reduce sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol. 2001;281 (5):H2241–2251.
  66. Gomez-Sanchez EP. Central hypertensive effects of aldosterone. Front Neuroendocrinol. 1997;18 (4):440–462.
  67. Farquharson CA, Struthers AD. Spironolactone increase nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I / angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101 (6):594–597.
  68. Bauersachs J, Heck M, Fraccarollo D et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39 (2):351–358.
  69. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37 (7):1800–1807.
  70. Moser DK, Stevenson WG, Woo MA, Stevenson LW. Timing of sudden death in patients with heart failure. J Am Coll Cardiol. 1994;24 (4):963–967.
  71. Muller JE, Stone PH, Turi ZG et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313 (21):1315–1322.
  72. Dyckner T. Relation of cardiovascular disease to potassium and magnesium deficiencies. Am J Cardiol. 1990;65 (23):44K-46K.
  73. Tsuji H, Venditti FJ Jr, Evans JC et al. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol. 1994;74 (3):232–235.
  74. Ramires FJ, Mansur A, Coelho O et al. Effect of spironolactone on ventri­cular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85 (10):1207–1211.
  75. Barr CS, Long CC, Hanson J et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995; (76):1259–1265.
  76. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78 (8):902–907.
  77. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
  78. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60 (10):820–825.
  79. de Gasparo M, Joss U, Ramjoué HP et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240 (2):650–656.
  80. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15 (8):709–716.
  81. Cook CS, Berry LM, Kim DH et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002;30 (12):1344–1351.
  82. Sadée W, Dagcioglu M, Schröder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973185 (3):686–695.
Mareev V. Yu., Skvortsov A. A. Effects of aldosterone blockade in patients with heart failure: a modern approach to the problem – eplerenone (part I). Russian Heart Failure Journal. 2011;12(3):170-176

To access this material please log in or register

Register Authorize
Ru En